Epithelial ovarian cancer – pipeline review, h2 2012
Upcoming SlideShare
Loading in...5

Like this? Share it with your network


Epithelial ovarian cancer – pipeline review, h2 2012

Uploaded on

2012 || Oncology || Epithelial Ovarian Cancer – Pipeline Review, H2 2012 || Aarkstore.com

2012 || Oncology || Epithelial Ovarian Cancer – Pipeline Review, H2 2012 || Aarkstore.com

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Epithelial Ovarian Cancer – Pipeline Review, H2 2012http://www.aarkstore.com/reports/Epithelial-Ovarian-Cancer-Pipeline-Review-H2-2012-220604.htmlRSS link of Global Markets Directhttp://www.aarkstore.com/feeds/Global-Markets-Direct.xmlSummaryGlobal Markets Direct’s, Epithelial Ovarian Cancer - Pipeline Review, H2 2012,provides an overview of the Epithelial Ovarian Cancer therapeutic pipeline. Thisreport provides information on the therapeutic development for Epithelial OvarianCancer, complete with latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in the therapeuticdevelopment for Epithelial Ovarian Cancer. Epithelial Ovarian Cancer - PipelineReview, H2 2012 is built using data and information sourced from Global MarketsDirect’s proprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer.- A review of the Epithelial Ovarian Cancer products under development bycompanies and universities/research institutes based on information derived fromcompany and industry-specific sources.
  • 2. - Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Table of contents:List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Epithelial Ovarian Cancer Overview 6Therapeutics Development 7An Overview of Pipeline Products for Epithelial Ovarian Cancer 7Epithelial Ovarian Cancer Therapeutics under Development by Companies 9Epithelial Ovarian Cancer Therapeutics under Investigation byUniversities/Institutes 10Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13Comparative Analysis 13Epithelial Ovarian Cancer Therapeutics – Products under Development byCompanies 14Epithelial Ovarian Cancer Therapeutics – Products under Investigation byUniversities/Institutes 15Companies Involved in Epithelial Ovarian Cancer Therapeutics Development 16Boehringer Ingelheim GmbH 16Amgen Inc. 17VentiRx Pharmaceuticals, Inc. 18Epithelial Ovarian Cancer – Therapeutics Assessment 19Assessment by Monotherapy Products 19Assessment by Combination Products 20Assessment by Route of Administration 21Assessment by Molecule Type 23Drug Profiles 25
  • 3. AMG 386 - Drug Profile 25Product Description 25Mechanism of Action 25R&D Progress 25List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Cholangiocellular Hepatoma – Pipeline Review, H2 2012Hormone Refractory Breast Cancer – Pipeline Review, H2 2012Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012Refractory Multiple Myeloma – Pipeline Review, H2 2012Epithelial Ovarian Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012
  • 4. Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1You can also request for sample page of above mention reports onsample@aarkstore.comFor More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585
  • 5. Email: enquiry@aarkstore.com